Lundbeck faces antitrust investigation
The European Commission has opened an antitrust investigation into drugs company Lundbeck, based on information acquired during its sector enquiry into the pharmaceutical industry
The enquiry, completed last year, investigated alleged abuse of competition law by pharmaceutical companies, leading to delays in market entry of generic medicines.
In particular, the enquiry examined allegations about the evergreening of patents, patent clusters and reverse-payment deals.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.